Drug Trial Radar · NCT01998984
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
266
Actual
Start
Jan 2014
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2 trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily treatment for 2, 3 or 4 consecutive days compared to vehicle gel
Conditions
- Actinic Keratosis
Interventions
ingenol mebutateDrug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Clearance of Actinic Keratosis Lesions (AKs)Time frame: At Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Long Island Skin Cancer and Dermatologic Surgery
Smithtown, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.